Eli Lilly and Co (NYSE:LLY) has delivered another major escalation in the obesity treatment race, unveiling late-stage trial data showing its experimental triple-agonist drug retatrutide helped some patients lose more than 30% of their body weight — results approaching levels traditionally associated with bariatric surgery.
The Phase 3 TRIUMPH-1 study tested retatrutide in adults with obesity or overweight and at least one weight-related condition, but without diabetes. At the highest 12-milligram dose, patients lost an average 28.3% of their body weight over 80 weeks, equivalent to about 70 pounds (31.9 kilograms). Nearly half (45.3%) of participants achieved at least 30% weight loss.
For participants with more severe obesity who continued into a blinded extension study, average weight loss stretched to 30.3% after 104 weeks.
The data further tightens Lilly’s grip on one of the pharmaceutical industry’s fastest-growing and most fiercely contested markets, where drugmakers are now competing not only on weight loss percentages, but also on convenience, tolerability and broader metabolic benefits.
Shares in Eli Lilly are now up more than 20% over the past month as investors continue betting the company can extend its lead beyond existing blockbuster obesity drugs Zepbound and Mounjaro.
Moving beyond GLP-1
The latest obesity drugs, including Novo Nordisk’s Wegovy and Lilly’s Zepbound, largely work by targeting GLP-1 pathways involved in appetite and blood sugar regulation.
Retatrutide goes a step further.
The once-weekly injectable activates three hormone receptors simultaneously — GIP, GLP-1 and glucagon — in an attempt to drive stronger metabolic effects. Lilly believes that broader mechanism could produce deeper and more sustained weight loss than earlier-generation therapies.
The numbers appear to support that belief.
At the lower 4-milligram dose, which required only one escalation step, patients still lost an average 19% of body weight at 80 weeks, while discontinuation rates due to adverse events remained comparable to placebo.
The higher doses, however, also carried the familiar gastrointestinal side effects now closely associated with incretin-based obesity therapies, including nausea, diarrhoea, constipation and vomiting.
A market becoming harder to dominate
The obesity drug boom has rapidly evolved from a breakthrough treatment story into a broader pharmaceutical arms race.
Analysts increasingly view the sector as potentially worth hundreds of billions of dollars annually over the coming decade as drugmakers target obesity, diabetes, cardiovascular disease, sleep apnoea and fatty liver disease through overlapping metabolic pathways. But competition is also intensifying.
Novo Nordisk remains dominant globally with Wegovy, while Lilly’s currently marketed Zepbound has gained market share quickly after producing stronger weight-loss data than earlier GLP-1 therapies. Now companies are trying to differentiate further.
Some are chasing higher efficacy. Others are focusing on oral pills rather than injections, easier dosing schedules, broader insurance access or fewer side effects.
Lilly is attempting to do several at once.
Alongside the retatrutide results, the company also recently released new data on its oral obesity pill Foundayo, known scientifically as orforglipron. In a post-hoc analysis of older adults aged 65 and over, patients achieved up to 13% average weight loss at 72 weeks without food or water restrictions attached to dosing.
That convenience factor could become increasingly important as the obesity market expands beyond early adopters and into broader primary care settings.
Beyond weight loss alone
Retatrutide’s significance extends beyond the headline weight-loss figures.
Lilly said the drug also delivered improvements across several cardiometabolic markers during the study, including waist circumference, triglycerides, blood pressure and inflammatory measures. That broader metabolic profile is becoming increasingly important as obesity treatments move deeper into mainstream healthcare and insurers look for evidence that these drugs can reduce longer-term complications tied to cardiovascular disease, diabetes and other chronic conditions.
Drugmakers are already expanding clinical programs accordingly. Lilly is studying retatrutide across multiple additional indications, including sleep apnoea, osteoarthritis pain, fatty liver disease and cardiovascular outcomes.
For investors, though, the immediate takeaway remains relatively straightforward: Lilly continues to push the upper limits of what obesity medicines can achieve — and, for now, the market appears convinced there is still room to run.